Arrowhead Research said this week that it has appointed Chad Mirkin to its newly established board of scientific strategy.
Mirkin is the director of the International Institute for Nanotechnology, and a professor of chemistry, medicine, and materials science and engineering at Northwestern University. He holds a BS from Dickinson College and a PhD in chemistry from Pennsylvania State University.
Alnylam Pharmaceuticals has appointed Edward Scolnick to its board of directors and scientific advisory board.
Scolnick is the director of the Psychiatry Initiative at the Broad Institute. Previously, he held a number of positions at Merck Research Laboratories including president. Before that, he worked for the National Cancer Institute and the National Heart Institute.
He holds an AB and MD from Harvard Medical School.
Regulus Therapeutics, a microRNA therapeutics joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, has named Peter Linsley as its CSO.
Linsley was previously executive director of cancer biology at Merck Research Laboratories. Before that, he held a number of roles at Rosetta Inpharmatics before it was acquired by Merck.
He holds a BS from Auburn University and a PhD from the Molecular Biology Institute of the University of California, Los Angeles.